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Assessment instrument by imaging site 
Differences in assessment instruments by imaging site are presented in Supplementary Table 1 below. Participants from each site were scanned on different scanners. 
Particularly, all participants except those from Barcelona were scanned on 3T scanners (Barcelona = 1.5T), which may have resulted in the observed site difference wherein 
ROI volumes from participants in Barcelona are significantly smaller (see Supplementary Tables 2 and 3). While cannabis use across the sites were quantified in either of 
joints, grams, or cones, units were converted to cones prior to analysis (https://ncpic.org.au/static/pdfs/ assessment-tools/timeline-followback.pdf).  	  
Supplementary Table 1 Assessment instruments by imaging site 
Participants Amsterdam 
N = 76 
Barcelona 
N = 55 
Wollongong 
N = 30 
Melbourne 
N = 100 
Inclusion 
criteria 
CB group >/= 10 days/mth, >/= 240 days 
over last 2 yrs 
First use age < 16, 14-28 
joints/week over last 2 yrs 
>/= 3-4 times/wk >/= 2 days/mth for at least 2 yrs 
HC group < 50 joints/lifetime, did not use in 
last yr 
< 15 times/lifetime, did not use in 
last mth 
No lifetime history of regular CB 
use, did not use in last yr 
</= 10 times/lifetime, did not use 
in last yr 
Exclusion 
criteria 
IQ < 80 </= 90 - < 80 
Axis I psychiatric 
disorders 
Assessed via MINI, medical 
history 
Assessed via PRISM, medical 
history 
SCID (psychotic screening), 
medical history 
SCID (depression and psychotic 
screening), medical history 
Illicit substance 
use except CB 
> 25 times/lifetime > 5 times/lifetime - > 50 times/past 10 yrs 
Urine test Positive for alcohol and other 
illicit drugs except CB 
Positive for other illicit drugs 
except CB 
Positive for other illicit drugs 
except CB 
Positive for other illicit drugs 
except CB 
Others General MRI contraindication, 
use of psychoactive medication 
Left-handed, female, general 
MRI contraindication, use of 
psychoactive medication 
Left-handed, general MRI 
contraindication, use of 
psychoactive medication 
General MRI contraindication, 
use of psychoactive medication 
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Scanner Model Phillips Intera General Electic Signa Excite Phillips Intera Siemens Team Trio 
Strength 3T 1.5T 3T 3T 
Measures  Amsterdam Barcelona Wollongong Melbourne 
IQ  Dutch version of NART (DART) WAIS-III vocabulary subscore a NART WASI  
Alcohol use  StDr/mth, AUDIT Age first drink, StDr/wk StDr/wk Age first drink, Age regular 
drink, StDr/mth, AUDIT 
Tobacco use  Age regular use, cig/day, cig/mth Age first use, age regular use, 
cig/day, cig/mth  
Age regular use, cig/day, cig/mth 
(extrapolated from cig/day) 
Age first use, age regular use, 
cig/day, cig/mth 
Cannabis use  Amsterdam 
N = 33 
Barcelona 
N = 29 
Wollongong 
N = 15 
Melbourne 
N = 63 
Onset first use Yes Yes Yes Yes 
Onset regular use (criteria) > weekly use >/= 4 times/wk  >/= 2 times/mth >/= 2 times/mth 
Frequency  Days/wk - Days/mth Days/mth 
Quantity b Current use Grams/wk Joints/mth Cones/mth Cones/mth 
 Lifetime use Self report estimate Extrapolated from onset age and 
use 
Self report estimate, including 
any heavier or lighter use period 
Self report estimate, including 
any heavier or lighter use period 
Dependence  MINI – score >/= 3 as dependent SDS – score >/= 4 as dependent - SDS – score >/= 4 as dependent 
a WAIS-III vocabulary subscale converted to an estimated full scale IQ by standardizing to the average IQ of CB users and HC respectively of the three other sites.  
b CB use quantity (joints or grams) was converted to cones (https://ncpic.org.au/static/pdfs/ assessment-tools/timeline-followback.pdf). 
*CB = cannabis, HC = healthy controls; wk = week, mth = month, yrs = years, MINI = Mini Neuropsychiatry International Interview (Lecrubier et al. 1997; Sheehan et al. 1997; Swift et al. 
1998), PRISM = Psychiatric Research Interview for Substance and Mental Disorders (	  http://www.columbia.edu/~dsh2/prism/, Hasin et al. 1996), SCID =	  Structured Clinical Interview for 
DSM Disorders (Spitzer et al. 1994; First et al. 2001), DART = Dutch version of the National Adult Reading Test (Schmand et al. 1991), WAIS-III = Wechsler Adult Intelligence Scale – Third 
Edition (Wechsler 1997), NART = National Adult Reading Test (Nelson 1982), WASI = Wechsler Abbreviated Scale of Intelligence (Wechsler 1999),  StDr = standard drinks, AUDIT = 
Alcohol Use Disorder Identification Test (Saunders et al. 1993), cig = cigarette, SDS = Severity of Dependence Scale (Gossop et al. 1995; van der Pol et al. 2013).  
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Demographic and ROI volumes for HC and CB by imaging site 
Demographic and substance use characteristics of participants by imaging site, along with any significant site effects, are presented in Supplementary Table 2. Amsterdam 
and Barcelona had the youngest samples (all male in Barcelona) and used significantly less cannabis (monthly and lifetime), followed by Melbourne, and then Wollongong. 
Participants from Wollongong meanwhile have the highest IQ, and used the most alcohol and cigarettes of all sites. CB users from Melbourne started using CB at a 
significantly younger age than those from Amsterdam and Wollongong. The only significant site by group effects in terms of demographic were found for IQ (p = .023) and 
monthly cigarette uss (p = .002). CB users had a significantly lower IQ than HC in Barcelona (p = .023) and Melbourne (p < .001) samples only. Meanwhile, HC from all 
four sites used fewer cigarettes than CB users, but did not differ between each other in monthly cigarette use; while CB users from Wollongong smoked the most cigarettes, 
followed by CB users from Melbourne and Amsterdam, and finally Barcelona. 
Site effect for the ROI comparisons from the main analysis are reported in Supplementary Table 2 as well. Participants from Barcelona had the smallest OFC (both 
medial and lateral), while participants from Amsterdam had the largest caudate. The larger ROI volume in Amsterdam likely reflects the younger age of participants 
(Walhovd et al. 2005), while the smaller ROI volume in Barcelona may represent differences in scanner field strength (higher scanner field strength is associated with larger 
volume (Han et al. 2006)).  However, no site by group interaction effect was found, suggesting that site effect did not skew or mask any HC vs. CB effects. 	  
Supplementary Table 2 Demographic, substance use characteristics, and ROI volumes of healthy controls (HC) and cannabis (CB) users by imaging site (Mean (SD); ROI 
volumes in mm3) 
 HC CB Site Effect 
 Amsterdam 
N = 43 
Barcelona 
N = 26 
Wollongong 
N = 15 
Melbourne 
N = 37 
Amsterdam 
N = 33 
Barcelona 
N = 29 
Wollongong 
N = 15 
Melbourne 
N = 63 
F/X2 p 
Age  21.98 
(2.46) 
22.57 
(3.36) 
35.00 
(10.08) 
29.95 
(11.29) 
21.32 
(2.39) 
21.03 
(2.34) 
38.99 (9.24) 32.67 
(11.07) 
49.88 <.001; Amst < Melb***, Amst < 
Woll***, Barc < Melb***, Barc < 
Woll***, Melb < Woll***a 
Gender  
(% M / F) 
62.79 / 
37.21 
100 / 0 93.33 / 6.67 48.65 / 
51.35 
66.67 / 
33.33 
100 / 0 93.33 / 6.67 46.03 / 
53.97 
55.94 <.001 
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IQ 104.86 
(7.25) 
109.26 
(10.47) 
113.45 
(8.07) 
112.32 
(12.72) 
104.18 
(5.44) 
103.58 
(10.71) 
109.37 (6.16) 101.83 
(12.96) 
3.22  .023; Amst < Woll**, Barc <  Woll*, 
Melb < Woll** 
Alcohol  
(StDr/mth)a 
21.44 
(26.76) 
12.43 
(10.52) 
21.79 (5.63) 26.72 
(4.39) 
23.64 
(23.85) 
21.14 
(15.38) 
26.37 (6.81) 28.06 
(3.51) 
3.28 .022; Amst < Woll*, Barc < Woll**, 
Melb < Woll* 
Tobacco  
(Cig/mth)a 
41.73 
(106.41) 
24.22 
(103.97) 
100.20 
(23.62) 
77.77 
(12.79) 
211.99 
(218.91) 
168.41 
(152.35) 
274.73 
(68.68) 
233.14 
(29.14) 
4.34 .005; Amst < Woll**, Barc < Woll**, 
Barc < Melb* 
Cannabis Use           
   Onset Regular  
   Use (years) 
- - - - 18.85 
(2.26) 
18.12 
(2.05) 
20.14 (5.25) 16.72 
(3.27) 
5.81 .001; Melb < Amst**, Melb < Woll** 
   Current Use  
   (cones/month) 
- - - - 158.51 
(115.95) 
224.13 
(138.20) 
634.13 
(545.45) 
404.97 
(308.94) 
12.33 <.001; Amst < Melb***, Amst < 
Woll***, Barc < Melb*, Barc < 
Woll***, Melb < Woll** 
   Lifetime Use  
   (cones) 
- - - - 4,738.64 
(4,275.06) 
15,611.28 
(12,577.01) 
177,772.50 
(205,672.08) 
74,579.21 
(75,833.71) 
26.53 <.001; Amst < Melb***, Amst < 
Woll***, Barc < Melb**, Barc < 
Woll***, Melb < Woll*** 
Intracranial 
Cavity (10^6) 
1.44 (0.22) 1.62 (0.12) 1.72 (0.15) 1.56 (0.15) 1.36 (0.18) 1.59 (0.13) 1.65 (0.10) 1.54 (0.14)   
Lateral 
OFC  
Left 8238.56 
(905.83) 
7691.00 
(819.29) 
8771.20 
(882.19) 
7858.86 
(871.29) 
8273.09 
(1012.49) 
7728.59 
(877.69) 
8031.00 
(905.51) 
7644.71 
(844.76) 
12.44 b <.001; Barc < Amst***, Barc < 
Woll*, Barc < Melb**, Melb < 
Amst* 
 Right 7191.09 
(902.04) 
8031.69 
(731.90) 
8751.33 
(1083.36) 
7757.41 
(815.22) 
6839.64 
(978.39) 
7706.69 
(925.15) 
7926.07 
(849.01) 
7518.59 
(921.74) 
  
Medial 
OFC 
Left 4712.93 
(611.28) 
5502.23 
(604.62) 
5921.67 
(803.90) 
5375.95 
(607.90) 
4570.42 
(692.96) 
5496.90 
(777.61) 
5700.47 
(594.56) 
5106.84 
(744.48) 
5.85 b .001; Barc < Amst**; Barc < Melb* 
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 Right 5782.37 
(600.14) 
5295.23 
(535.52) 
6091.73 
(797.08) 
5397.16 
(518.76) 
5364.55 
(687.07) 
5385.93 
(751.12) 
5504.80 
(725.33) 
5132.95 
(652.93) 
  
Caudate  Left 3977.13 
(405.45) 
3868.95 
(502.19) 
4303.71 
(569.12) 
3817.29 
(488.19) 
3793.47 
(473.73) 
3893.28 
(558.45) 
3880.48 
(608.80) 
3676.41 
(577.91) 
18.68 b <.001; Barc < Amst***, Melb < 
Amst***, Woll < Amst** 
 Right 4332.80 
(459.78) 
4077.08 
(547.87) 
4237.88 
(634.89) 
3720.92 
(469.49) 
4135.25 
(503.70) 
4087.04 
(613.56) 
3781.87 
(565.86) 
3588.19 
(611.47) 
  
a StDr/mth = standard drinks per month, Cig/mth = cigarettes smoked per month, Amst = Amsterdam, Barc = Barcelona, Melb = Melbourne, Woll = Wollongong 
b repeated-measures analysis of covariance (ANCOVA) – hemisphere = within subjects measure, imaging site, gender, group = between-subject factors, age, IQ, monthly alcohol and tobacco 
use = covariates – as per main analysis. 
* p < .05, ** p < .01, *** p < .001 
 
Demographic and ROI volumes for CB-nondep and CB-dep by imaging site 
Demographic, substance use characteristics, and ROI volumes of CB-nondep and CB-dep group by imaging site, along with any significant site effects, are presented in 
Supplementary Table 3. Similar to the previous table, Amsterdam and Barcelona had younger participants who used significantly less cannabis (monthly and lifetime) than 
Melbourne. CB users from Melbourne also started using cannabis at a significantly younger age than CB users from Amsterdam. The only significant site by dependence 
group interaction effect was found for monthly CB use (p = .009), whereby CB-nondep users from all sites, and CB-dep users from Amsterdam and Barcelona did not differ 
in monthly CB use, but CB-dep users from Melbourne used significantly more cannabis per month than all other groups and sites.  
Site effect for the ROI comparisons from the main analysis are reported in Supplementary Table 3 as well. Participants from Barcelona had a smaller lateral OFC 
than participants from Amsterdam. While the primarily larger volume of CB-nondep users from Amsterdam (compared to every other group) may have driven the 
dependence-related effect on lateral OFC volume, there was no site by dependence interaction effect. There was no significant site, or site by dependence interaction effect on 
medial OFC volume. The trend of CB-dep users having smaller medial OFC than CB-nondep users was present in all sites (when analysed separately), suggesting that the 
smaller medial OFC in CB-dep users in the main analysis is robust across sites. Finally, participants from Amsterdam had a larger caudate than participants from Barcelona 
and Melbourne. There is also a site by dependence interaction effect for caudate volume (p = .047), with CB-nondep Amsterdam users having the largest caudate. 
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Supplementary Table 3 Demographic, substance use characteristics, and ROI volumes of non-dependent (CB-nondep) and dependent (CB-dep) cannabis users by imaging 
site (Mean (SD); ROI volumes in mm3) 
 CB-nondep CB-dep Site effect 
 Amsterdam 
N = 21 
Barcelona 
N = 7 
Melbourne 
N = 22 
Amsterdam 
N = 12 
Barcelona 
N = 18 
Melbourne 
N = 40 
F/X2 p 
Age 20.87 (2.16) 20.14 (1.35) 36.04 (11.51) 22.10 (2.66) 20.78 (2.16) 30.83 (10.25) 31.58 <.001; Amst < Melb***, Barc < 
Melb***a 
Gender (% M / F) 61.90 / 38.10 100 / 0 45.45 / 54.55 75.00 / 25.00 100 / 0 45.00 / 55.00 23.20 <.001 
IQ 103.10 (4.70) 98.95 (10.33) 104.48 (14.86) 106.08 (6.30) 104.21 (10.79) 100.00 (11.63) 0.64 .528 
Alcohol 
(StDr/mth)a 
21.05 (24.48) 27.14 (26.28) 20.22 (26.10) 28.17 (23.02) 17.94 (9.85) 21.76 (26.59) 0.15 .859 
Tobacco 
(Cig/mth)a 
202.05 (207.92) 131.43 (82.55) 298.43 (299.15) 229.39 (245.52) 158.56 (178.88) 244.34 (189.20) 2.58 .080 
Cannabis Use         
   Onset Regular  
   Use (years) 
18.54 (1.96) 17.43 (1.99) 17.26 (3.22) 19.39 (2.72) 18.33 (2.06) 16.53 (3.42) 6.06 .003; Melb < Amst** 
   Current Use  
   (cones/month) 
177.03 (125.56) 286.00 (220.90) 255.87 (244.34) 126.10 (92.96) 201.91 (98.25) 479.20 (312.64) 12.32 <.001; Amst < Melb***, Barc < 
Melb** 
   Lifetime Use  
   (cones) 
4350.00 
(4038.32) 
12,534.00 
(8,406.45) 
69,214.13 
(58,145.03) 
5418.75 
(4766.87) 
18,004.17 
(14,755.26) 
78,527.13 
(85,791.12) 
20.23 <.001; Amst < Melb***, Barc < 
Melb*** 
Intracranial 
Cavity (10^6) 
1.35 (0.20) 1.62 (0.13) 1.51 (0.14) 1.38 (0.16) 1.58 (0.14) 1.56 (0.13)   
Lateral Left 8426.19 7687.43 7568.86 8005.17 7699.33 7633.20 7.96 b .001; Barc < Amst** 
	   8	  
OFC (1115.85) (848.72) (758.93) (771.57) (916.47) (839.46) 
 Right 6980.86 
(1006.88) 
7884.43 
(855.05) 
7365.27 
(744.94) 
6592.50 
(975.15) 
7615.39 
(991.34) 
7570.43 
(996.26) 
  
Medial 
OFC 
Left 4660.05 
(720.33) 
5602.86 
(563.20) 
5174.09 
(816.76) 
4413.58 
(641.39) 
5367.22 
(901.95) 
5052.63 
(695.87) 
1.32 b .271 
 Right 5435.10 
(791.09) 
5479.14 
(704.24) 
5321.32 
(718.69) 
5241.08 
(457.49) 
5266.39 
(767.34) 
5013.23 
(595.17) 
  
Caudate Left 3854.74 
(478.93) 
3883.84 
(459.47) 
3519.06 
(526.95) 
3686.24 
(464.87) 
3842.11 
(570.97) 
3771.25 
(596.16) 
6.31 b .003; Barc < Amst*, Melb < 
Amst** 
 Right 4205.93 
(523.80) 
4049.37 
(576.73) 
3360.55 
(565.50) 
4011.54 
(461.51) 
4064.21 
(632.87) 
3728.42 
(602.94) 
  
a StDr/mth = standard drinks per month, Cig/mth = cigarettes smoked per month, Amst = Amsterdam, Barc = Barcelona, Melb = Melbourne 
b repeated-measures analysis of covariance (ANCOVA) – hemisphere = within subjects measure, imaging site, gender, group = between-subject factors, age, IQ, monthly alcohol and tobacco 
use = covariates – as per main analysis. 
* p < .05, ** p < .01, *** p < .001 
 
Correlation of ROI against IQ, monthly tobacco use 
Preliminary correlations between ROI (lateral OFC, medial OFC, caudate) volumes and IQ in all sites combined (range of r = .09 – 13, p ≥ .04, Supplementary Fig. 1) 
suggest they were not associated after correcting for multiple comparison (critical value = .027, Benjamini and Yekutieli’s modified FDR method (Benjamini and Yekutieli 
2001). Similarly, when correlations were split across individual sites, IQ was not correlated with any of the ROI volumes (range of r = -.13 – 29, p ≥ .08). Monthly cigarette 
use was also not correlated with ROI volumes, whether in all sites combined (range of r = -.07 – -.01, p ≥ .29, Supplementary Fig. 1), or in individual sites (range of r = -.26 – 
.03, p ≥ .14). 
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Supplementary Fig. 1. Scatterplot of correlation of regions of interest, ROI volumes (lateral orbitofrontal cortex (OFC), medial OFC, caudate) against IQ and monthly 
cigarette use (cig/mth). Volumes are averaged across hemispheres, adjusted for intracranial volume and age. Critical value after FDR correction = .027 (Benjamini and 
Yekutieli 2001).  
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